244.76
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$246.22
Offen:
$245.81
24-Stunden-Volumen:
656.93K
Relative Volume:
0.62
Marktkapitalisierung:
$35.89B
Einnahmen:
$5.02B
Nettoeinkommen (Verlust:
$1.31B
KGV:
27.47
EPS:
8.91
Netto-Cashflow:
$1.56B
1W Leistung:
-0.42%
1M Leistung:
+4.54%
6M Leistung:
-1.83%
1J Leistung:
+18.14%
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RMD
Resmed Inc
|
244.76 | 36.04B | 5.02B | 1.31B | 1.56B | 8.91 |
![]()
ISRG
Intuitive Surgical Inc
|
552.41 | 196.08B | 8.71B | 2.48B | 1.75B | 6.82 |
![]()
BDX
Becton Dickinson Co
|
173.01 | 49.62B | 20.87B | 1.50B | 2.59B | 5.24 |
![]()
ALC
Alcon Inc
|
85.38 | 43.30B | 9.93B | 1.12B | 1.58B | 2.25 |
![]()
COO
The Cooper Companies, Inc.
|
80.12 | 15.87B | 3.93B | 415.40M | 384.70M | 2.06 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
2025-01-16 | Eingeleitet | Goldman | Buy |
2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
2024-12-13 | Eingeleitet | Stifel | Hold |
2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
2024-09-04 | Herabstufung | Needham | Buy → Hold |
2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2023-09-06 | Hochstufung | Needham | Hold → Buy |
2023-09-05 | Herabstufung | UBS | Buy → Neutral |
2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2023-05-23 | Eingeleitet | UBS | Buy |
2023-04-14 | Eingeleitet | Mizuho | Buy |
2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
2022-10-12 | Eingeleitet | Jefferies | Hold |
2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
2021-08-02 | Herabstufung | Needham | Buy → Hold |
2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
2021-06-21 | Bestätigt | Needham | Buy |
2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
2021-03-16 | Hochstufung | Needham | Hold → Buy |
2020-11-02 | Hochstufung | UBS | Neutral → Buy |
2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-02-03 | Eingeleitet | CLSA | Underperform |
2020-01-31 | Herabstufung | UBS | Buy → Neutral |
2020-01-10 | Eingeleitet | Oppenheimer | Perform |
2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
2019-07-29 | Hochstufung | UBS | Neutral → Buy |
2019-07-16 | Herabstufung | UBS | Buy → Neutral |
2019-05-06 | Hochstufung | UBS | Neutral → Buy |
2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
Actigraphy Devices Market Report 2025-2034 | Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape - GlobeNewswire Inc.
ResMed CFO Executes Stock Transaction Under Rule 10b5-1 Plan - TipRanks
ResMed CFO Brett Sandercock sells $891,285 in stock By Investing.com - Investing.com South Africa
Hedge Fund and Insider Trading News: Bill Ackman, Paul Tudor Jones, Chase Coleman, John Paulson, Polus Capital Management, VFC Corp (VFC), ResMed Inc (RMD), and More - Insider Monkey
ResMed CFO Brett Sandercock sells $891,285 in stock - Investing.com
ResMed’s SWOT analysis: sleep tech giant faces growth challenges, new markets - Investing.com
ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Are Wall Street Analysts Bullish on ResMed Stock? - Inkl
Are Wall Street Analysts Bullish On ResMed Stock? - Barchart.com
Is it Worth Retaining ResMed Stock in Your Portfolio Now? - Nasdaq
Insider Sell: Witte De Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
ResMed CFO Sells Shares - marketscreener.com
Why Kogan, Monash IVF, OFX, and ResMed shares are falling today - MSN
Down 5%: What's going on with the ResMed share price? - MSN
RMD ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of ResMed Inc. Shareholders Who Lost Money - ACCESS Newswire
Morgan Stanley sees ‘modest’ earnings impact to ResMed from Apnimed - Yahoo Finance
Should you buy the dip in the ResMed share price? - MSN
ResMed Draws Analyst Skepticism After Apnimed Announces Positive Results From Investigational Sleep Apnea Drug: Retail’s Unmoved By Stocktwits - Investing.com India
ResMed Draws Analyst Skepticism After Apnimed Announces Positive Results From Investigational Sleep Apnea Drug: Retail’s Unmoved - MSN
Positive Phase 3 Trial Results for RMD's Sleep Apnea Treatment | - GuruFocus
ResMed (RMD) Faces Potential Market Challenges from New Sleep Ap - GuruFocus
ResMed (RMD) Faces Potential Market Challenges from New Sleep Apnea Treatment | RMD Stock News - GuruFocus
Here's Why ResMed (RMD) is a Strong Growth Stock - Yahoo Finance
ResMed (NYSE:RMD) Seems To Use Debt Rather Sparingly - simplywall.st
Apnea Therapy Market Is Booming Worldwide 2025-2032 | ResMed Inc., Koninklijke Philips N.V. - openPR.com
Resmed (RMD) Partners with Rugby Tour to Promote Sleep Health | - GuruFocus
ResMed named Sleep Partner of the Qatar Airways British & Irish Lions Tour - TipRanks
Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 - The Spec
Patient Monitoring Stocks Q1 Teardown: ResMed (NYSE:RMD) Vs The Rest - Yahoo Finance
Resmed Inc Updates Dividend Exchange Rate for CDI Holders - TipRanks
Levi & Korsinsky Reminds ResMed Investors of the Ongoing Investigation into Potential Violations of Securities LawsRMD - ACCESS Newswire
ResMed CEO Michael Farrell sells $1.95m in stock By Investing.com - Investing.com Canada
Resmed Insider Sold Shares Worth $1,948,003, According to a Recent SEC Filing - marketscreener.com
ResMed CEO Michael Farrell sells $1.95m in stock - Investing.com
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
Resmed prevails over Cleveland Medical in CPAP patent review - BioWorld MedTech
Is ResMed Inc.'s (NYSE:RMD) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Ex-Dividend Reminder: Seaboard, KB Home and ResMed - Nasdaq
ResMed Inc Reports Changes in CDIs and Securities for April 2025 - TipRanks
Jim Cramer on Viemed Healthcare (VMD): “Interesting, But I’m a ResMed Guy” - Yahoo Finance
ResMed Wins Invalidation of Sleep Apnea Tech Patent After Remand - Bloomberg Law News
Is It Smart To Buy ResMed Inc. (NYSE:RMD) Before It Goes Ex-Dividend? - Yahoo Finance
ResMed Corporation: GLP-1 Demand Generation Strategy to Expand Customer Base & Strengthen Their Position! - Smartkarma
Intuitive wins new FDA nod for single port robot; Resmed buys diagnostic facility - MedTech Dive
This ResMed Insider Reduced Their Stake By 72% - Yahoo Finance
Resmed acquires independent diagnostic testing facility VirtuOx - Yahoo Finance
Resmed Acquires Virtual Care Company VirtuOx - Medical Product Outsourcing
ResMed (RMD) Expands with VirtuOx Acquisition - GuruFocus
Resmed Acquires VirtuOx - Nasdaq
ResMed Buys VirtuOx for Undisclosed sum - marketscreener.com
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):